Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neurofibromatosis 1 6Neurofibrosarcoma 2Neurofibroma, Plexiform 2Sarcoma 1Pancreatic Neoplasms 1

Interventions

anlotinib 3Injections 3Doxorubicin 3toripalimab 1spartalizumab 1penpulimab 1pemigatinib 1pazopanib 1montelukast 1liposomal doxorubicin 1eribulin 1chlorhexidine gluconate 1camrelizumab 1bexmarilimab 1apatinib 1X-Rays 1Trabectedin 1Temozolomide 1Tablets 1Surgical Procedures, Operative 1Sodium Chloride 1Radiotherapy 1Proton Therapy 1Positron Emission Tomography Computed Tomography 1Nivolumab 1Neoadjuvant Therapy 1Negative-Pressure Wound Therapy 1KP 1339 1Ipilimumab 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Sarcoma × AZD 6244 × Clear all
NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡